B-cell malignancies

Dec 15, 2023

Date of Abstract presentation11th December 2023IndicationsRelapsed or Refractory (R/R) B-Cell MalignanciesAbstract Number4401Abstract typePoster The preliminary results from this ongoing clinical trial, unveiled at the ASH 2023 conference, demonstrated that, among the efficacy evaluable patients (n=28), BGB-1667...

Jun 11, 2019

Lilly tests the efficacy of Tirzepatide-a novel dual GIP, GLP-1 agonist Eli Lilly is planning to test its diabetes drug Tirzepatide in a phase 2b Non-Alcoholic Steatohepatitis (NASH) trial. Tirzepatide, also known as LY3298176, has been excellent in reducing body weight and blood sugar in patients with poorly co...

Mar 03, 2015

Antibody–drug conjugates (ADCs), a new weapon of 21st Century for fighting Cancer Traditional cancer chemotherapy was having harsh side effects and also leads to systemic toxicity. The approach was also referred to as the carpet-bombing strategy for fighting cancer. Traditional chemotherapy does not discriminate b...